Last reviewed · How we verify
cyclosporine ophthalmic emulsion Formulation B
cyclosporine ophthalmic emulsion Formulation B is a Small molecule drug developed by Allergan. It is currently in Phase 1 development.
At a glance
| Generic name | cyclosporine ophthalmic emulsion Formulation B |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease (PHASE2)
- Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclosporine ophthalmic emulsion Formulation B CI brief — competitive landscape report
- cyclosporine ophthalmic emulsion Formulation B updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about cyclosporine ophthalmic emulsion Formulation B
What is cyclosporine ophthalmic emulsion Formulation B?
cyclosporine ophthalmic emulsion Formulation B is a Small molecule drug developed by Allergan.
Who makes cyclosporine ophthalmic emulsion Formulation B?
cyclosporine ophthalmic emulsion Formulation B is developed by Allergan (see full Allergan pipeline at /company/allergan).
What development phase is cyclosporine ophthalmic emulsion Formulation B in?
cyclosporine ophthalmic emulsion Formulation B is in Phase 1.